TY  - JOUR
TI  - CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma
Y1  - 2018///
SN  - 1479-5876
A1  - Cai, Xiaobo
A1  - Li, Jun
A1  - Yuan, Xiaodong
A1  - Xiao, Jingbo
A1  - Dooley, Steven
A1  - Wan, Xinjian
A1  - Weng, Honglei
A1  - Lu, Lungen
SP  - 1
EP  - 7
CY  - London
JF  - Journal of Translational Medicine
N2  - Background; CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC).

Methods: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-?1, p-Smad2 and epithelial?mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed.

Results: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133+ patients had significantly higher metastasis rate than those without CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133+ patients had shorter overall and disease-free survival time as compared to the CD133? patients. Furthermore, 90.9% of CD133+ patients developed cancer recurrence, as compared to 64.3% of CD133? patients (p = 0.02). As compared to CD133? patients, tumor cells in CD133+ patients demonstrated high levels of TGF-?/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.

Conclusions: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-? related EMT alterations.
UR  - https://archiv.ub.uni-heidelberg.de/volltextserver/24316/
PB  - BioMed Central
VL  - 16
ID  - heidok24316
IS  - 50
AV  - public
ER  -